Edward S. Kim, MD

Dr. Kim on the Role of Biomarker Testing in Treatment Decisions for Solid Tumors

September 7th 2022

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

Dr. Kim on the Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

July 13th 2022

Edward S. Kim, MD, MBA, discusses the importance of trastuzumab deruxtecan in HER2-mutated non–small cell lung cancer.

Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

June 6th 2021

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

Dr. Kim Discusses Data From the IMpower150 Trial in Nonsquamous NSCLC

November 6th 2019

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses data from the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).

Dr. Kim on Clinical Trial Eligibility Criteria in Lung Cancer

October 25th 2019

Edward S. Kim, MD, discusses clinical trial eligibility criteria in lung cancer.

Dr. Kim on the KEYNOTE-189 Trial in Metastatic NSCLC

October 12th 2019

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the randomized, double-blind, phase III KEYNOTE-189 trial in patients with previously untreated, metastatic nonsquamous non–small cell lung cancer.

Dr. Kim Discusses the Primary Efficacy Results From the B-F1RST Trial in NSCLC

October 23rd 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

Dr. Kim Discusses the Impact of the PACIFIC Trial in NSCLC

March 20th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

Dr. Kim Addresses Concerns About Hyperprogression in NSCLC

March 14th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the prevalence of hyperprogression and pseudoprogression in patients who receive immunotherapy.

Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

December 21st 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Dr. Kim on the Importance of Biomarker Testing for Lung Cancer

November 29th 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

Dr. Kim on the Need for EAPathways as a Decision-Making Tool

October 27th 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the need to develop EAPathways as an improved decision-making tool for oncologists during the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Dr. Kim on Combination Therapies in Lung Cancer

September 13th 2016

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC

August 18th 2016

Dr. Edward Kim on ASCO's TAPUR Trial

June 9th 2016

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the significance of the TAPUR clinical trial, which is being conducted by ASCO.

Dr. Kim Discusses Detecting EGFR and KRAS Mutations from Cell-Free Plasma DNA of NSCLC Patients

June 16th 2014

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of improved and complete enrichment co-amplification at lower denaturation temperature method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of patients with non-small cell lung cancer (NSCLC).